AIM: To design a theranostic capsule using the virus-like nanoparticle of the hepatitis E virus modified to display breast cancer cell targeting functional group (LXY30). METHODS: Five surface-exposed residues were mutated to cysteine to allow conjugation to maleimide-linked chemical groups via thiol-selective linkages. Engineered virus-like nanoparticles were then covalently conjugated to a breast cancer recognized ligand, LXY30 and an amine-coupled near-infrared fluorescence dye. RESULTS: LXY30-HEV VLP was checked for its binding and entry to a breast cancer cell line and for tumor targeting in vivo to breast cancer tissue in mice. The engineered virus-like nanoparticle not only targeted cancer cells, but also appeared immune silent to native hepatitis E virus antibodies due to epitope disruption at the antibody-binding site. CONCLUSION: These results demonstrate the production of a theranostic capsule suitable for cancer diagnostics and therapeutics based on surface modification of a highly stable virus-like nanoparticle.
AIM: To design a theranostic capsule using the virus-like nanoparticle of the hepatitis E virus modified to display breast cancer cell targeting functional group (LXY30). METHODS: Five surface-exposed residues were mutated to cysteine to allow conjugation to maleimide-linked chemical groups via thiol-selective linkages. Engineered virus-like nanoparticles were then covalently conjugated to a breast cancer recognized ligand, LXY30 and an amine-coupled near-infrared fluorescence dye. RESULTS:LXY30-HEVVLP was checked for its binding and entry to a breast cancer cell line and for tumor targeting in vivo to breast cancer tissue in mice. The engineered virus-like nanoparticle not only targeted cancer cells, but also appeared immune silent to native hepatitis E virus antibodies due to epitope disruption at the antibody-binding site. CONCLUSION: These results demonstrate the production of a theranostic capsule suitable for cancer diagnostics and therapeutics based on surface modification of a highly stable virus-like nanoparticle.
Authors: Pitchanee Jariyapong; Li Xing; Nienke E van Houten; Tian-Cheng Li; Wattana Weerachatyanukul; Benjamin Hsieh; Carlos G Moscoso; Chun-Chieh Chen; Masahiro Niikura; R Holland Cheng Journal: Vaccine Date: 2012-10-26 Impact factor: 3.641
Authors: Tian-Cheng Li; Naokazu Takeda; Tatsuo Miyamura; Yoshiharu Matsuura; Joseph C Y Wang; Helena Engvall; Lena Hammar; Li Xing; R Holland Cheng Journal: J Virol Date: 2005-10 Impact factor: 5.103
Authors: Shao W Li; Jun Zhang; Yi M Li; Shan H Ou; Guo Y Huang; Zhi Q He; Sheng X Ge; Yang L Xian; Shu Q Pang; Mun H Ng; Ning S Xia Journal: Vaccine Date: 2005-04-22 Impact factor: 3.641
Authors: Tom S Y Guu; Zheng Liu; Qiaozhen Ye; Douglas A Mata; Kunpeng Li; Changcheng Yin; Jingqiang Zhang; Yizhi Jane Tao Journal: Proc Natl Acad Sci U S A Date: 2009-07-21 Impact factor: 11.205
Authors: Soledad Palameta; Andrea J Manrique-Rincón; Jessica M Toscaro; Isadora F Semionatto; Matheus C Fonseca; Rhubia S M Rosa; Luciana P Ruas; Paulo S L Oliveira; Marcio C Bajgelman Journal: Mol Ther Oncolytics Date: 2022-02-17 Impact factor: 7.200
Authors: Marie C Stark; Mo A Baikoghli; Tanja Lahtinen; Sami Malola; Li Xing; Michelle Nguyen; Marina Nguyen; Aria Sikaroudi; Varpu Marjomäki; Hannu Häkkinen; R Holland Cheng Journal: Sci Rep Date: 2017-12-06 Impact factor: 4.379